| Identification | Back Directory | [Name]
Bulaquine | [CAS]
79781-00-3 | [Synonyms]
Bulaquine
CDRI-80/53
compound 80-53
N-[(3-Acetyl-4,5-dihydrofuran)-2-yl]-N'-(6-methoxy-8-quinolinyl)-1,4-pentanediamine
1-[4,5-Dihydro-2-[[4-[(6-methoxyquinoline-8-yl)amino]pentyl]amino]furan-3-yl]ethanone
2(3H)-Furanone, dihydro-3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]- | [Molecular Formula]
C21H27N3O3 | [MDL Number]
MFCD00890219 | [MOL File]
79781-00-3.mol | [Molecular Weight]
369.46 |
| Hazard Information | Back Directory | [Description]
Bulaquine is a derivative of primaquine that was introduced in India in combination with
chloroquine as a treatment against malaria. The compound is prepared by condensation
of primaquine with 3-acetyl-y-butyrolactone in presence of a catalytic amount of base.
Bulaquine kills the latent tissue stage (hypnozoites) of the parasite Plasmodium vivax
accumulated in the liver and responsible for relapses. Its efficient anti-relapse activity was
demonstrated against sporozoite induced Plasmodium cynomolgi infection in rhesus
monkey. Bulaquine is safer than primaquine, the preceding candidate against malaria
relapse. Although it is stable at pH 7-8, bulaquine is hydrolyzed to primaquine under acidic
conditions. | [Originator]
CDRI (India) | [Uses]
Bulaquine is anti-malarial drug. | [Definition]
ChEBI: Bulaquine is an aminoquinoline. | [Brand name]
Aablaquin |
|
|